Tags

Type your tag names separated by a space and hit enter

Phase II trial on the effects of Silexan in patients with neurasthenia, post-traumatic stress disorder or somatization disorder.
Phytomedicine 2012; 19(8-9):665-71P

Abstract

Silexan, a novel lavender oil preparation for oral use, has been authorized in Germany for the treatment of states of restlessness during anxious mood. An open-label, exploratory trial was performed to assess the potential of the medicinal product in the treatment of restlessness caused by anxiety as related to several disorders. Outcome measures included the Symptom Checklist-90-Revised (SCL-90-R), von Zerssen's Depression Scale (D-S), the 36-item Short Form Health Survey Questionnaire (SF-36), and a sleep diary. 50 male and female patients with neurasthenia (ICD-10 F48.0), post-traumatic stress disorder (PSD; F43.1), or somatization disorder (F45.0, F45.1) were included to receive 1 × 80 mg/day Silexan over 6 weeks; 47 could be analyzed for efficacy as full analysis set. At baseline, patients suffered from restlessness (96%), depressed mood (98%), sleep disturbances (92%), or anxiety (72%). Of those, resp. 62%, resp. 57%, resp.51%, resp. 62% showed improvements during treatment (p < 0.001). For all patients, mean D-S score decreased by 32.7% and SCL-90-R Global Severity Index by 36.4% as compared to baseline, (p < 0.001), while the SF-36 Mental Health Score increased by 48.2% (p < 0.001). Waking-up frequency (p = 0.002), Waking-up duration (p < 0.001) and morning tiredness (p = 0.005) were reduced, while efficiency of sleep (p = 0.018) and mood (p = 0.03) improved. Patients suffering from neurasthenia or PSD showed comparable improvements with most outcomes. The results in this trial justify to further investigate Silexan in disorders with accompanying restlessness caused by sub-threshold anxiety. Adverse reactions, predominantly gastrointestinal complaints, were judged as mild or moderate.

Authors+Show Affiliations

Charité - Universitaetsmedizin Berlin and Immanuel Krankenhaus, Berlin, Germany. Bernhard.Uehleke@my-campus-berlin.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22475718

Citation

Uehleke, B, et al. "Phase II Trial On the Effects of Silexan in Patients With Neurasthenia, Post-traumatic Stress Disorder or Somatization Disorder." Phytomedicine : International Journal of Phytotherapy and Phytopharmacology, vol. 19, no. 8-9, 2012, pp. 665-71.
Uehleke B, Schaper S, Dienel A, et al. Phase II trial on the effects of Silexan in patients with neurasthenia, post-traumatic stress disorder or somatization disorder. Phytomedicine. 2012;19(8-9):665-71.
Uehleke, B., Schaper, S., Dienel, A., Schlaefke, S., & Stange, R. (2012). Phase II trial on the effects of Silexan in patients with neurasthenia, post-traumatic stress disorder or somatization disorder. Phytomedicine : International Journal of Phytotherapy and Phytopharmacology, 19(8-9), pp. 665-71. doi:10.1016/j.phymed.2012.02.020.
Uehleke B, et al. Phase II Trial On the Effects of Silexan in Patients With Neurasthenia, Post-traumatic Stress Disorder or Somatization Disorder. Phytomedicine. 2012 Jun 15;19(8-9):665-71. PubMed PMID: 22475718.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Phase II trial on the effects of Silexan in patients with neurasthenia, post-traumatic stress disorder or somatization disorder. AU - Uehleke,B, AU - Schaper,S, AU - Dienel,A, AU - Schlaefke,S, AU - Stange,R, Y1 - 2012/04/03/ PY - 2011/11/16/received PY - 2012/02/29/revised PY - 2012/02/29/accepted PY - 2012/4/6/entrez PY - 2012/4/6/pubmed PY - 2012/12/10/medline SP - 665 EP - 71 JF - Phytomedicine : international journal of phytotherapy and phytopharmacology JO - Phytomedicine VL - 19 IS - 8-9 N2 - Silexan, a novel lavender oil preparation for oral use, has been authorized in Germany for the treatment of states of restlessness during anxious mood. An open-label, exploratory trial was performed to assess the potential of the medicinal product in the treatment of restlessness caused by anxiety as related to several disorders. Outcome measures included the Symptom Checklist-90-Revised (SCL-90-R), von Zerssen's Depression Scale (D-S), the 36-item Short Form Health Survey Questionnaire (SF-36), and a sleep diary. 50 male and female patients with neurasthenia (ICD-10 F48.0), post-traumatic stress disorder (PSD; F43.1), or somatization disorder (F45.0, F45.1) were included to receive 1 × 80 mg/day Silexan over 6 weeks; 47 could be analyzed for efficacy as full analysis set. At baseline, patients suffered from restlessness (96%), depressed mood (98%), sleep disturbances (92%), or anxiety (72%). Of those, resp. 62%, resp. 57%, resp.51%, resp. 62% showed improvements during treatment (p < 0.001). For all patients, mean D-S score decreased by 32.7% and SCL-90-R Global Severity Index by 36.4% as compared to baseline, (p < 0.001), while the SF-36 Mental Health Score increased by 48.2% (p < 0.001). Waking-up frequency (p = 0.002), Waking-up duration (p < 0.001) and morning tiredness (p = 0.005) were reduced, while efficiency of sleep (p = 0.018) and mood (p = 0.03) improved. Patients suffering from neurasthenia or PSD showed comparable improvements with most outcomes. The results in this trial justify to further investigate Silexan in disorders with accompanying restlessness caused by sub-threshold anxiety. Adverse reactions, predominantly gastrointestinal complaints, were judged as mild or moderate. SN - 1618-095X UR - https://www.unboundmedicine.com/medline/citation/22475718/Phase_II_trial_on_the_effects_of_Silexan_in_patients_with_neurasthenia_post_traumatic_stress_disorder_or_somatization_disorder_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0944-7113(12)00084-0 DB - PRIME DP - Unbound Medicine ER -